NASDAQ:PLXP PLx Pharma (PLXP) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free PLXP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3,000 shsAverage Volume12.96 million shsMarket Capitalization$603,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get PLx Pharma alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About PLx Pharma Stock (NASDAQ:PLXP)PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… PLXP Stock News HeadlinesJanuary 30, 2024 | investing.comProtalix Biotherapeutics Inc (PLX)January 22, 2024 | morningstar.comVertex Pharmaceuticals Inc VRTXApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.October 23, 2023 | investing.comVietnam National Petroleum Group (PLX)August 21, 2023 | uk.investing.comPLx Pharma Inc (PLXPQ)April 21, 2023 | seekingalpha.comPLXPQ PLx Pharma Inc.April 13, 2023 | marketwatch.comPLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE(R) and Substantially All of its AssetsApril 12, 2023 | msn.comWhy PLx Pharma Shares Are Nosediving TodayApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 12, 2023 | msn.comWhy iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving PremarketApril 11, 2023 | msn.comWhy PLx Pharma Shares Are Down Over 40% TuesdayApril 11, 2023 | finance.yahoo.comPLx Pharma Inc. Receives Nasdaq Delisting NoticeApril 11, 2023 | msn.comShort Volatility Alert: Plx Pharma IncDecember 22, 2022 | msn.comPLx Pharma's Return On Capital Employed InsightsNovember 11, 2022 | seekingalpha.comPLx Pharma (PLXP) Q3 2022 Earnings Call TranscriptNovember 11, 2022 | seekingalpha.comPLx Pharma down after Q3 revenue fell 94% Y/YNovember 10, 2022 | finance.yahoo.comPLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business UpdateNovember 10, 2022 | finance.yahoo.comPLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue EstimatesNovember 10, 2022 | msn.comEarnings Preview: PLx PharmaOctober 26, 2022 | finance.yahoo.comPLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business UpdateSeptember 12, 2022 | finance.yahoo.comBaseball Legend John Smoltz Featured on PLx Pharma’s Social ChannelsSeptember 5, 2022 | finance.yahoo.comPLx Pharma Inc. (NASDAQ:PLXP) drops to US$21m and insiders who purchased earlier this year lose another US$52kAugust 20, 2022 | finance.yahoo.comPLXP Aug 2022 5.000 callAugust 15, 2022 | seekingalpha.comPLx Pharma downgraded at Oppenheimer after Q2 missAugust 12, 2022 | marketwatch.comPLx Pharma to Explore Strategic Alternatives, Reduces TeamAugust 12, 2022 | apnews.comSurvey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mgAugust 12, 2022 | markets.businessinsider.comPLx Pharma Q2 Loss Top Estimates, But Revenues Miss; Stock Down 15%See More Headlines Receive PLXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PLXP CUSIPN/A CIK1497504 Webwww.plxpharma.com Phone(973) 409-6541Fax713-842-3052Employees16Year Founded2002Profitability EPS (Most Recent Fiscal Year)($1.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,130,000.00 Net Margins-606.91% Pretax Margin-606.91% Return on Equity-291.11% Return on Assets-119.43% Debt Debt-to-Equity RatioN/A Current Ratio4.79 Quick Ratio4.28 Sales & Book Value Annual Sales$4.54 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / BookN/AMiscellaneous Outstanding Shares29,138,000Free Float26,530,000Market Cap$603,000.00 OptionableNot Optionable Beta3.79 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesNatasha GiordanoPresident, Chief Executive Officer & DirectorRita M. O'ConnorCFO, Head-Manufacturing & Supply ChainMayme Lou RoettigExecutive Medical DirectorThomas L. LongVP-Manufacturing & Technical OperationsLawrence R. PerkinsChief Restructuring OfficerKey CompetitorsAditxtNASDAQ:ADTXChina SXT PharmaceuticalsNASDAQ:SXTCBellerophon TherapeuticsNASDAQ:BLPHAllarity TherapeuticsNASDAQ:ALLREvelo BiosciencesNASDAQ:EVLOView All Competitors PLXP Stock Analysis - Frequently Asked Questions How were PLx Pharma's earnings last quarter? PLx Pharma Inc. (NASDAQ:PLXP) issued its quarterly earnings results on Friday, November, 12th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $0.09. The biotechnology company earned $6.60 million during the quarter, compared to analyst estimates of $4.10 million. PLx Pharma had a negative net margin of 606.91% and a negative trailing twelve-month return on equity of 291.11%. The business's revenue was up 560.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.40) earnings per share. What other stocks do shareholders of PLx Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other PLx Pharma investors own include Energy Transfer (ET), Fulcrum Therapeutics (FULC), CymaBay Therapeutics (CBAY), VIVUS (VVUS), Paratek Pharmaceuticals (PRTK), Sorrento Therapeutics (SRNE), Cornerstone Strategic Value Fund (CLM), NewLink Genetics (NLNK), SCYNEXIS (SCYX) and Viking Therapeutics (VKTX). When did PLx Pharma IPO? PLx Pharma (PLXP) raised $68 million in an initial public offering on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers. This page (NASDAQ:PLXP) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PLx Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
